[Skip to Content]
[Skip to Content Landing]
Views 854
Citations 0
Research Letter
December 29, 2016

Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States

Author Affiliations
  • 1Department of Urology, Weill Cornell Medicine–New York Presbyterian Hospital, New York
  • 2Department of Radiation Oncology, Brigham and Women’s Hospital, Boston, Massachusetts
  • 3Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York
  • 4Department of Gynecology, Columbia College of Physicians and Surgeons, New York, New York
JAMA Oncol. Published online December 29, 2016. doi:10.1001/jamaoncol.2016.5465

Following the introduction of prostate-specific antigen (PSA) screening in the early 1990s, there has been a 50% decline in prostate cancer–specific mortality and more than a 70% decline in the incidence of metastases at diagnosis.1 Given the recent declines in PSA screening and prostate cancer incidence, we sought to assess the effect of these changes on prostate cancer presentation.

First Page Preview View Large
First page PDF preview
First page PDF preview
×